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Background: Atherosclerosis is a systemic inflammatory disease, with common
inflammatory processes implicated in both atheroma vulnerability and blood-brain
barrier disruption. This prospective multimodal imaging study aimed to measure directly
the association between systemic atheroma inflammation (“atheroinflammation”) and
downstream chronic cerebral small vessel disease severity.
Methods: Twenty-six individuals with ischemic stroke with ipsilateral carotid
artery stenosis of >50% underwent 18fluoride-fluorodeoxyglucose-positron emission
tomography within 2 weeks of stroke. Small vessel disease severity and white matter
hyperintensity volume were assessed using 3-tesla magnetic resonance imaging also
within 2 weeks of stroke.
Results: Fluorodeoxyglucose uptake was independently associated with more severe
small vessel disease (odds ratio 6.18, 95% confidence interval 2.1–18.2, P < 0.01 for
the non-culprit carotid artery) and larger white matter hyperintensity volumes (coefficient
= 14.33mL, P < 0.01 for the non-culprit carotid artery).
Conclusion: These proof-of-concept results have important implications for our
understanding of the neurovascular interface and potential therapeutic exploitation
in the management of systemic atherosclerosis, particularly non-stenotic disease
previously considered asymptomatic, in order to reduce the burden of chronic
cerebrovascular disease.
Keywords: atherosclerosis, blood-brain barrier, carotid artery, cerebrovascular disease/stroke, leukoaraiosis,
carotid-cerebrovascular interface
INTRODUCTION
Atherosclerosis is a systemic inflammatory disease that may cause stroke through destabilization
of atherosclerotic plaques and consequent thromboemboli (1). However, it is increasingly
recognized that the effects of atherosclerosis extend beyond a single “vulnerable plaque,” and
instead involve the overall burden from the systemic nature of atherosclerosis on the individual
“vulnerable patient” (2).
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This is particularly true in the neurovascular setting, where
the brain represents an end-organ highly sensitive to insult from
the general metabolic environment. The presence of vascular
risk factors may exacerbate inflammation within atheroma
(atheroinflammation) (3–6), disrupt blood-brain barrier (BBB)
integrity (7), and promote neuroinflammation in individuals
without stroke, potentially priming the brain for injury (8).
Furthermore, systemic inflammation itself may also promote
an increase in BBB permeability (9). Consequently, chronic
pro-inflammatory states, such as that seen in atherosclerosis,
may have a role in compromising BBB integrity. Such BBB
dysfunction is implicated in the development of chronic
cerebral small vessel disease (SVD) (10); focal lacunar infarcts
or subcortical diffuse white matter change (leukoaraiosis)
characterized by neuronal loss, demyelination, and gliosis (10).
SVD is a major risk factor for both stroke and dementia (11), and
is independently associated with poorer recovery after stroke (12)
and stroke recurrence (13).
The direct relationship between carotid atherosclerosis and
SVD remains unclear. Although leukoaraiosis is positively
associated with both carotid intima-media thickness (IMT) and
presence of atheroma, negative associations have been reported
with the degree of luminal stenosis (14). These inconsistent
findings may be due to variability in the extent of inflammation
within atheroma, which is independent of stenosis severity
(15). Inflammation within atheroma can be measured in vivo
by positron emission tomography (PET) using 18fluoride-
fluorodeoxyglucose (FDG), a radionuclide analog of glucose (16).
FDG uptake is increased in symptomatic carotid atheroma (15),
and correlates with histological macrophage density but not
plaque size (17).
This study examines the direct association between carotid
artery atheroinflammation, measured by FDG-PET/CT, and
the severity of cerebral SVD. We hypothesized that increased




The Imaging Carotid Atherosclerosis in the Recovery
and Understanding of Stroke Severity (ICARUSS) Study
prospectively recruited individuals presenting with an ischemic
stroke within the previous seven days due to ipsilateral common
or internal carotid artery stenosis of ≥50% measured on
computed tomography angiography (CTA) [using the North
American Symptomatic Carotid Endarterectomy Trial method
(18)] at Addenbrooke’s Hospital, Cambridge, United Kingdom.
Cardiovascular risk factors and stroke severity were recorded at
baseline. Only individuals with evidence of brain infarction on
diffusion-weighted imaging (DWI) were enrolled. The minimum
age for study eligibility was 40 years. Individuals with atrial
fibrillation were excluded.
Anonymized imaging reads were performed for the full study
cohort after study completion, with readers (NRE, JMT, JW,
MMC) blinded to the clinical data. PET and MRI analyses were
analyzed independently and matched with clinical information
and each other only after analysis of the full cohort was complete.
All participants provided written informed consent in
accordance with the Declaration of Helsinki. The study
protocol was approved by a national research ethics committee
(Nottingham One Research Ethics Committee, 14/EM/0128).
PET/CT Protocol
FDG-PET/CT (Discovery 690 GE Healthcare, Little Chalfont,
UK) scans were performed with 64-slice computed tomography
within 14 days of ischemic stroke. Participants fasted for 6 h
prior to injection. Participants were injected intravenously with
a target of 250 MBq of FDG (sourced from Erigal Ltd, Keele,
UK), followed by a 90-min uptake time, as per previous work
(19). A silence protocol (minimal vocalization, only small sips
of water permitted) was adopted during this uptake period to
reduce physiological tracer uptake in neighboring structures. In
participants without diabetes, blood glucose concentrations were
confirmed as ≥7.0 mmol/L prior to tracer injection. Participants
with diabetes mellitus were instructed to take their usual oral
antidiabetic medications as normal, but insulin was omitted
within the 4 h prior to imaging.
PET imaging datasets were analyzed using OsiriX (version
5.7.1, OsiriX Imaging Software, Geneva, Switzerland). Co-
registered PET and CT images were resampled to 3mm slice
thickness and regions of interest (ROIs) drawnmanually on fused
PET/CT images along the common carotid and internal carotid
artery to encompass the region 0.9 cm proximal and 3 cm distal
to the carotid bifurcation as per established methodology (15).
ROIs were then transferred onto co-registered PET to produce
standardized uptake values of the maximum uptake within the
ROI (SUVmax). To compensate for blood pooling, the tissue SUV
was adjusted for venous SUV – the average of mid-luminal ROIs
in the jugular vein over five contiguous 3mm slices without
evidence of spill-over from neighboring structures – to give the
maximum target-to-background ratio (TBRmax); a measure of
radiotracer uptake validated for use in vascular PET imaging (17).
TBRmax for culprit and non-culprit carotid arteries were
compared for the most diseased segment (MDS) and whole vessel
(WV). The MDS considers the most diseased 9mm of the artery
(based on tracer uptake) and represents the mean of the TBRmax
of the ROIs in three contiguous axial slices where the central
ROI constitutes the point of highest tracer uptake in the artery as
per previous methodology (15). The WV is the median of tracer
uptake across all 14 axial slices of the artery. An experienced
reader (MMC) performed reproducibility and quality assurance
by repeating ROIs in 20% of the FDG-PET/CTs.
MRI Protocol
Participants had brain imaging performed within 2 weeks of
stroke using a 3-tesla whole body magnetic resonance imaging
(MRI) scanner (MR750, GE Healthcare, Waukesha, WI) with
a 12-channel head, neck, and spine coil with a brachial plexus
attachment. Sequences included T1, T2, DWI, fluid-attenuated
inversion recovery (FLAIR), and gradient echo sequences.
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Assessment of Cerebral Small Vessel
Disease
The extent of WMH was measured both semi-quantitatively
and quantitatively. Semi-quantitative measures were taken from
the FLAIR sequence using the scoring system proposed by
Fazekas et al. (20) and later modified by Pantoni et al. (21). The
Fazekas score has been dichotomized previously (22), and in
this study we dichotomized global (whole brain) periventricular
and deep white matter hyperintensities according to no/mild or
moderate/severe leukoaraiosis [using the visual scale described
by Pantoni et al. (21)] given that the majority of our cohort
showed some small vessel disease.
Quantitative measurement of WMHs was performed by
measuring WMHs in the hemisphere contralateral to the acute
stroke and multiplying by two. Measurement was conducted
using semi-automatic ROI marking using Jim Imaging Software
(version 7.0, Xinapse Systems Ltd., Essex, United Kingdom).
MRI interpretation was performed by two experienced readers
for all scans (NRE and JW). Intra-class correlation coefficients for
inter-rater reliability were calculated subsequently.
Inflammatory Biomarker
Venous blood was drawn at the time of FDG-PET/CT
for high-sensitivity C-reactive protein (hsCRP) as a marker
of inflammation.
Statistical Analysis
Continuous data was tested for normality using the Shapiro-
Wilk method. Parametric data was reported as mean ± standard
deviation (SD) and non-parametric data reported as median
and inter-quartile range (IQR). Unpaired groups were compared
using t-testing (parametric readings) or Wilcoxon rank sum
testing (non-parametric readings). Comparison between culprit
and contralateral non-culprit arteries in the same individual used
equivalent paired testing. Associations were tested using two-
tailed Spearman’s rho correlation (non-parametric or ordinal
data) or Pearson’s correlation coefficient (parametric data).
Multivariable analysis (logistic regression and linear
regression) initially included all variables considered in
univariable analysis (age, sex, smoking status, diabetes mellitus,
hypertension, pre-stroke statin, pre-stroke antiplatelet,
cardiovascular history), with goodness of fit optimized
subsequently with backwards elimination of variables to
achieve the lowest Akaike information criteria.
Tracer uptake was compared across stenosis categories
(“1–29%,” “30–49,” “50–69%,” “70–89%,” “90–99%”) in both
symptomatic and asymptomatic arteries using Kruskal-Wallis
one-way ANOVA testing (for non-parametric data).
The cut-off for statistical significance was set at P = 0.05.
Data was analyzed using R (version 3.6.1, 2019, R Foundation for
Statistical Computing, Vienna, Austria).
Data Availability
The corresponding author had full access to all the data in
the study and takes responsibility for its integrity and the data
analysis. The full anonymized dataset is available upon reasonable
request from the corresponding author.
TABLE 1 | Clinical characteristics of study cohort (n = 26).
Mean age (years) 74.8 (SD 9.7)
Men 18 (69.2%)
Median BMI 26 (IQR 3.9)
Smoking history (current or ex-smokers) 17 (65.4%)
Diabetes mellitus 4 (15.4%)
Hypertension 17 (65.4%)
Pre-stroke statin 9 (34.6%)
Pre-stroke antiplatelet 8 (30.8%)
Cardiovascular history (previous ischemic heart disease/
myocardial infarction)
8 (30.8%)
Median National Institutes of Health Stroke Scale (NIHSS) 4.5 (IQR 10.75)
Thrombolysed 6 (23.1%)
Modal degree of symptomatic stenosis 70–89%
RESULTS
Study Population
Of the 31 participants recruited to the ICARUSS study, 28
underwent FDG-PET/CT (of the three recruited who did not
undergo scanning: two deteriorated clinically, becoming too
unwell to continue in the study, and one was unable to complete
imaging due to claustrophobia).
Of this 28, 26 had imaging suitable for analysis (one
participant had an uninterpretable PET scan and one
subject declined MRI). All participants had bilateral carotid
atherosclerosis. Eight (30.8%) participants had co-existent
coronary artery disease, and four (15.4%) had a clinical diagnosis
of peripheral arterial disease. Clinical characteristics are shown
in Table 1.
All acute infarcts were cortical in their distribution, consistent
with probable artery-to-artery embolization. Reflecting this, in all
cases the carotid pathology was felt by the clinical team to be the
causative etiology for the acute infarct. The median DWI lesion
volume was 3.36ml (IQR 14.4 ml).
PET Tracer Uptake in Culprit and
Non-culprit Atherosclerotic Plaque
FDG uptake was significantly higher in the culprit artery than
in the contralateral non-culprit carotid artery for both the MDS
[median TBRmax (IQR) 2.08 (0.52) vs. 1.89 (0.40), respectively,
P < 0.001] and WV measures of uptake [median TBRmax
(IQR) 1.92 (0.41) vs. 1.71 (0.31), respectively, P < 0.001]. No
relationship was observed between FDG MDS TBRmax and the
degree of luminal stenosis (P = 0.91). There was a moderate
association between hsCRP and non-culprit WV TBRmax (rs =
0.50, P = 0.02). Inter-rater reliability of FDG reads was 0.93.
Chronic Small Vessel Disease
Of the 26 participants, 15 (57.7%) had no/mild leukoaraiosis,
11 (42.3%) had moderate/severe leukoaraiosis. The pattern
of disease was predominantly peri-ventricular. The median
WMH volume was 3.11ml (IQR 7.43ml). The group with
moderate/severe leukoaraiosis were older than those with
no/mild leukoaraiosis (mean age 79.4 ± 9.7 vs. 71.5 ± 8.5 years,
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Mean age (SD) (years) 71.5 (± 8.5) 79.4 (± 9.7) P = 0.04
Number of males (%) 11 (73.3%) 7 (63.3%) P = 0.60
Mean BMI (SD) 26.0 (± 4.2) 28.3 (± 5.3) P = 0.26
Current/former smoker
(%)
10 (66.7%) 7 (63.3%) P = 0.87
Diabetes mellitus (%) 1 (6.7%) 3 (27.3%) P = 0.15
Hypertension (%) 11 (73.3%) 6 (54.5%) P = 0.32
Pre-stroke statin (%) 7 (46.7%) 2 (18.2%) P = 0.13
Pre-stroke antiplatelet (%) 5 (33.3%) 3 (27.3%) P = 0.74
History of cardiovascular
disease (%)
5 (33.3%) 3 (27.3%) P = 0.74
Total cholesterol 4.55 (± 1.3) 4.5 (± 0.88) P = 0.91
Median NIHSS (IQR) 5 (12) 4 (8) P = 0.70
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9.2 (± 4.8) 8.9 (± 4.7) P = 0.88
P = 0.04), otherwise there were no other significant differences
in clinical characteristics between the cohorts (Table 2).
Multiple logistic regression showed FDG uptake to be
independently associated with severity of leukoaraiosis, for
both plaque and average whole vessel and in both culprit
and contralateral non-culprit arteries (Table 3; Figure 1). The
strongest associations were for the non-culprit artery, in
particular the WV uptake [adjusted OR 6.18 (95% confidence
interval 2.1–18.2), P < 0.01]. This model also suggests a lower
odds of moderate/severe leukoaraiosis in individuals taking
statins and increased odds of more severe small vessel disease
with increasing age. The effects of diabetes and smoking were
inconsistent (Table 3).
Quantitative measures of WMH produced a similar pattern.
On univariable analysis, there was no relationship between
culprit carotid MDS or WV TBRmax (rs = 0.30, P = 0.14 and
rs = 0.20, P = 0.34, respectively). In contrast, there was a trend
of increasing strength of association betweenWMH volume with
median non-culprit MDS TBRmax (rs = 0.39, P = 0.05), and the
WV TBRmax of the non-culprit carotid (rs = 0.50, P = 0.01).
Linear regression of WMH volume, adjusting for
cardiovascular risk factors, broadly supported the findings
in the semi-quantitative analysis. Again, FDG TBRmax was
independently associated with increased WMH volumes for
diffuse measures of atheroma inflammation (non-culprit artery
readings and the median whole vessel uptake in the culprit
carotid), but not when considering the focal uptake in the culprit
plaque (Table 4). Furthermore, this analysis also indicated a
consistent independent positive association between age and
WMH volume, and a negative association between statin use
and WMH volume, in-keeping with the results observed in the
semi-quantitative analysis. There were no significant interactions
between these variables.
Inter-rater reproducibility of Fazekas scoring had an ICC of
0.91 across all scans. Inter-rater reproducibility ofWMHvolumes
had an ICC of 0.99.
DISCUSSION
Our study is novel in relating the presence of leukoaraiosis
to the physiological activity within systemic atherosclerosis
measured using PET, rather than simply the degree of anatomical
luminal stenosis. We demonstrate an independent association
between atheroinflammation within carotid atherosclerosis and
the severity of small vessel disease.
This relationship, and the strength of the regression models
themselves, was stronger when considering the contralateral
non-culprit artery rather than the culprit artery. The non-
culprit artery is likely more representative of the overall burden
of systemic atheroinflammation, in effect acting as a disease
“barometer,” as suggested by the correlation between neighboring
arterial regions demonstrated by Rudd et al. (23). In contrast,
the most diseased segment of the culprit symptomatic artery
represents a region with potentially disproportionate uptake – a
peak focus of inflammation possibly accentuated by the rupture
itself – that may not be reflective of the global burden of
atheroinflammation throughout the body. Supporting this, our
results indicate more diffuse measures of FDG uptake in the
culprit artery (i.e., the WV) are similar to those from the
non-culprit artery. Given that WMHs represent chronic disease
developing over a longer time course than acute stroke, it
is therefore likely that the non-culprit artery gives a better
representation of the long-term pathophysiology to which the
brain has been exposed.
A possible mechanism linking atheroinflammation and SVD
is the action of matrix metalloproteinases (MMPs), which may
act locally and systemically. A single vulnerable plaque may
rupture through MMP-mediated disruption of the fibrous cap
(1, 24), but the elevated plasma concentrations (particularly
of MMP-9) seen in atherosclerosis may also have important
systemic effects (25, 26). MMP-9 is implicated in blood-brain
barrier dysfunction (27–29), where increased permeability may
promote the development of leukoaraiosis (30, 31). Previous
studies have demonstrated an association between FDG uptake
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TABLE 3 | Multiple logistic regression for moderate/severe leukoaraiosis severity for focal (MDS) and whole vessel (WV) FDG uptake in culprit and non-culprit carotid
arteries.
Culprit artery Non-culprit artery
MDS TBRmax Adjusted R
2
= 0.48 (P < 0.01)
MDS TBRmax Adjusted R
2
= 0.62 (P < 0.001)
OR (95% CI) Significance OR (95% CI) Significance
FDG uptake 2.14 (1.07–4.28) P = 0.04 FDG uptake 3.98 (1.84–8.59) P < 0.01
Age 1.03 (1.01–1.05) P < 0.01 Smoking 5.55 (1.23–25.0) P = 0.04
Pre-stroke statin 0.64 (0.46–0.89) P = 0.02 Age 1.03 (1.02–1.05) P < 0.001
Smoking 2.96 (0.66–13.32) P = 0.17 Pre-stroke statin 0.71 (0.54–0.93) P = 0.02
WV TBRmax Adjusted R
2
= 0.49 (P < 0.001)
WV TBRmax Adjusted R
2
= 0.57 (P < 0.001)
OR (95% CI) Significance OR (95% CI) Significance
FDG uptake 1.52 (1.06–2.17) P = 0.03 FDG uptake 6.18 (2.10–18.2) P < 0.01
Age 1.03 (1.01–1.05) P < 0.01 Age 1.03 (1.01–1.05) P < 0.01
Pre-stroke statin 0.63 (0.46–0.86) P < 0.01 Pre-stroke statin 0.72 (0.53–0.97) P = 0.04
Diabetes 2.15 (1.41–3.28) P < 0.01
Smoking 8.34 (1.14–61.0) P = 0.05
FDG uptake refers to per unit increase in the stipulated TBRmax .
FIGURE 1 | Carotid FDG uptake according to leukoaraiosis severity. Left: (A):
axial FLAIR showing no/mild leukoaraiosis (white arrow) with (C): associated
low carotid FDG uptake (brown arrows); Right: (B): axial FLAIR showing
moderate/severe leukoaraiosis (red arrow) with (D): higher associated carotid
FDG uptake (blue arrows). Both FDG-PET/CT images are set to the same
scale, with the scale bar showing FDG SUV.
and serum MMP-9 concentrations (23, 32). A 12-week course
of atorvastatin 40 mg/day resulted in significant reductions in
both atheroma TBR and MMP-9, with a moderate correlation
between the reduction in plaque TBR and reduction in MMP-
9 concentration (33). These relationships, and those between
MMP-9 levels and blood-brain barrier dysfunction (27–29), and
between blood-brain barrier permeability and the development
of leukoaraiosis (30, 31, 34), indicate an association between
the chronic atheroinflammation within carotid plaques and the
development of leukoaraiosis.
Our finding that FDG uptake did not relate to the
degree of luminal stenosis may explain the previously-
reported inconsistent findings in the association between
leukoaraiosis and the degree of stenosis (14), where plaques
with similar degrees of stenosis may have different levels of
atheroinflammation. The positive associations between SVD
and increased IMT or presence of plaque are in-keeping with
this hypothesis, as they may represent an earlier stage of
atherogenesis (and one more associated with inflammation) than
the degree of stenosis, where there may be more variability in
plaque activity from highly inflamed early atheroma to older
quiescent plaques.
Previous work has reported inconsistent associations between
leukoaraiosis and a range of vascular risk factors (35). A
notable exception is age, which most studies have found
to be independently associated with the development of
WMHs (13, 36). Our findings support this. Furthermore,
the independent association of statin therapy with reduced
SVD is potentially consistent with the pleiotropic effects of
statins and hence relevant to the inflammatory hypothesis.
The role of statins in WMH progression remains a subject of
debate: in the PROSPER study there was no effect on WMH
progression with pravastatin, though this cohort had low rates
of atherosclerosis (37). In contrast, progression of confluent
WMHs was found to be reduced by the use of pre-stroke
statin therapy (38).
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TABLE 4 | Linear regression for white matter hyperintensity volume (mL) for focal (MDS) and whole vessel (WV) FDG uptake in culprit and non-culprit carotid arteries.
Culprit artery Non-culprit artery












TBRmax 3.53 P = 0.08 TBRmax 9.38 P < 0.01
Age 0.50 P < 0.01 Age 0.50 P < 0.001
Pre-stroke statin −12.6 P < 0.01 Pre-stroke statin −9.03 P = 0.02
Pre-stroke antiplatelet 6.05 P = 0.15 Pre-stroke antiplatelet 5.69 P = 0.12












TBRmax 8.91 P < 0.01 TBRmax 14.33 P < 0.01
Age 0.52 P < 0.001 Age 0.48 P < 0.001
Pre-stroke statin −11.54 P < 0.01 Pre-stroke statin −8.86 P = 0.01
Pre-stroke antiplatelet 6.69 P = 0.07 Pre-stroke antiplatelet 6.33 P = 0.08
Limitations and Future Work
Although the high sensitivity of PET enables detection of
subtle physiological changes, allowing statistically significant
differences to be detected despite small sample sizes, the
limited size of our study means that further validation
through replication in a larger cohort or meta-analysis would
be advantageous.
Related to this, some caution must be exercised when
interpreting the regression analyses given the relatively small
sample size. The use of the Akaike information criteria in
backwards elimination to optimize best-fit ensures that the
selected models explain the greatest amount of variation using
the fewest number of independent variables, hence reducing the
risk of overadjustment bias. In our linear and logistic models,
the consistent inclusion of age and pre-stroke statin in such
optimized models is biologically plausible and supported by the
existing literature as discussed above. Their presence is likely
to be on the causal pathway, thereby reducing overadjustment
bias further. Although the final models typically include three
to four covariables for the study size of 26 participants, and
hence not meet the “rule of ten” for the ratio of outcomes to
variables, such a rule of thumb has been argued to be either
too conservative or potentially of limited evidence basis (39, 40).
However, further replication and validation in larger studies to
accommodate more variables will be advantageous to reduce
further the risk of overadjustment bias.
We did not measure MMPs in this study, though the
association between FDG uptake and MMP-9 has been reported
previously (23). Future studies measuring MMPs and other
inflammatory biomarkers may further elucidate the mechanistic
link underlying associations observed here.
In this study, we considered only carotid atherosclerosis. The
overall burden of systemic atheroinflammation will reflect the
totality of disease in other arterial territories (including coronary
arteries, aorta, and peripheral arterial disease). However,
previous work has demonstrated that atheroinflammation is
strongly associated across neighboring arterial territories, and
consequently the carotids (particularly the diffuse measure of
uptake in the non-culprit artery, WV TBRmax) may serve as good
surrogates of systemic atheroinflammation (23). Furthermore,
we found a moderate association between the non-culprit WV
TBRmax and serum hsCRP, suggesting that the carotid uptake
is a reasonable reflection of systemic inflammation. Future
work considering the global burden of atheroinflammation
for the individual, incorporating atheroinflammation across
coronary, aortic, and peripheral arterial disease, as well as
comparison against healthy controls would help elucidate this
relationship further.
Although highly sensitive, FDG uptake is non-specific.
Although the measures taken here improve its specificity for
inflammation, replication using newer radiotracers with higher
specificity for inflammatory cells, such as 68Ga-DOTATATE (19),
would help characterize this relationship.
To elucidate the mechanisms underlying the associations
observed in this study, future work should consider a range
of biomarkers of systemic inflammation, and imaging of BBB
integrity alongside carotid and brain imaging.
CONCLUSION
The observed association between carotid atheroinflammation
and the presence of more severe small vessel disease has
implications for our understanding of the neurovascular
interface and may have future influence on how we manage
“asymptomatic” atherosclerosis, with atheroinflammation
treated more aggressively with anti-inflammatory agents.
Canakinumab (a monoclonal antibody targeting interleukin-1β)
has shown promise for reducing cardiovascular outcomes after
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myocardial infarction (41), whilst colchicine has also been found
to reduce cardiovascular outcomes in those with coronary artery
disease (42, 43). Evidence for the benefit of such agents related
specifically to carotid atherosclerosis is currently lacking (44),
though the Colchicine for Prevention of Vascular Inflammation
in Non-cardio Embolic Stroke (CONVINCE) study will consider
the use of colchicine in a stroke setting. Such therapeutic
approaches targeting systemic atheroinflammation may have an
important role for reducing the burden of chronic small vessel
disease and its clinical sequelae.
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